Cell Line and Membrane Market
REPORT SCOPE:
The scope of this report is broad and covers various types of products available in the cell line and membrane market and potential application sectors across various industries. The cell line and membrane market is segmented by cell line product type and membrane type. Revenue forecasts from 2018 to 2023 are given for each product, application and end user with estimated values derived from the total revenue of manufacturers.
The report also includes a discussion of the major players across each region in the cell line and membrane market. Further, it explains the major drivers and regional dynamics of the global cell line and membrane market and current trends within the industry.
The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors in the cell line and membrane market.
REPORT INCLUDES:
The scope of this report is broad and covers various types of products available in the cell line and membrane market and potential application sectors across various industries. The cell line and membrane market is segmented by cell line product type and membrane type. Revenue forecasts from 2018 to 2023 are given for each product, application and end user with estimated values derived from the total revenue of manufacturers.
The report also includes a discussion of the major players across each region in the cell line and membrane market. Further, it explains the major drivers and regional dynamics of the global cell line and membrane market and current trends within the industry.
The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors in the cell line and membrane market.
REPORT INCLUDES:
- 79 data tables and 60 additional tables
- Identification of applications of cell lines in drug development, diagnostics, and molecular biology
- Description of advancements in cell lines for cancer-based therapies
- Details of CAR-T Cell and immune check point inhibitor therapy
- Comparative study of autologous vs allogenic cells manufacturing process
- Explanation of increasing adoption of cell line technologies in cell-based assay and surging demand of antibody production as a driving force to the cell line market
- Detailed profiles of the major vendors in the global cell line and membrane market, including ATCC, GE Healthcare, Lonza Group Ltd., Sartorius, Thermo Fisher Scientific and Wuxi AppTec
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET OVERVIEW
Introduction
Market Potential
Regulatory Framework
United States
European Union
China
India
Japan
Brazil
Investment Analysis
Industry Growth Drivers
Advancement in Technologies Accelerating the Scale-up of Cell Lines
High Investment in Cell Culture Technology
Increasing Adoption of Cell Line Technologies in Cell-Based Assays
Surging Demand for Antibody Production
High Investments by Pharmaceutical and Biotechnology Companies in Drug Development
CHAPTER 4 MARKET BREAKDOWN BY PRODUCT
Type of Cell Line
Development of Cell Lines and Cell Culture
Immunotherapy Cell Lines
Ion Channel Cell Lines
GPCR Cell Lines
Cell Signaling Pathway Cell Lines
Gene Knockout Cell Lines
Cancer Cell Lines
Others
Type of Cell Membrane
Natural
Synthetic
CHAPTER 5 MARKET BREAKDOWN BY END USER
Biopharmaceutical Companies
Contract Research Organizations (CROs)
Academic and Research Institutes
Forensic Science Laboratories
Food and Beverage Companies
Application of Cell Lines and Cell Cultures
The Benefits of Using Plant Cell Lines:
Microbes for Food and Beverage Production
Cell Lines in Clean Meat
Diagnostic Centers
Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research in Diagnostic Centers
Cell Membrane Proteomics Can Potentially Identify Breast Cancer
Others
CHAPTER 6 MARKET BREAKDOWN BY APPLICATION
Drug Discovery and Development
Application of Cell Line and Membrane in Drug Discovery and Development Process
Surging Utilization of Cell Lines in Cancer Pharmagenomics
Clinical Trials
Basic Research
Benefits of Cell Line in Research
Toxicity Screening
Biopharmaceutical Production
The Use of Human Cell Line for Biopharmaceutical Production
The Use of CHO Cells for Biopharmaceutical Production
Driver
Drug Screening
Driver
Forensic Testing
Cell Line Authentication
Tissue Engineering
Stem Cell Applications in Tissue Engineering
Driver
CHAPTER 7 MARKET BREAKDOWN BY REGION
North America
U.S.
Canada
Europe
U.K.
Germany
France
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
Australia
ROAPAC
RoW (Rest of the World)
Latin America
Middle East and Africa
CHAPTER 8 CELL LINE AND MEMBRANE MARKET INDUSTRY STRUCTURE
Procurement of Raw Materials
Quality
Terms and Conditions
Cost Effective Components
Manufacturing/Development Process
End Users
Factors Affecting Cell Line and Membrane Market
Innovation within the Industry
Various Gene Engineering Approaches
Advancements in Cell Lines for Cancer-Based Therapies
CAR T-Cell Lines and Immune Checkpoint Inhibitors
Autologous vs. Allogenic Cells Manufacturing Process
Competitive Analysis
CHAPTER 9 COMPANY PROFILES
ABZENA
ACM BIOLABS
ATCC
BD BIOSCIENCES
BIOIVT
CATALENT INC.
CELL BIOLABS INC.
CORNING INC.
CREATIVE BIOLABS
ETUBICS CORP.
GE HEALTHCARE
IXCELLS BIOTECHNOLOGIES
LONZA GROUP LTD.
MI BIORESEARCH INC.
MERCK MILLIPORE
MILTENYI BIOTEC
NOVUS BIOLOGICALS
ROCKLAND IMMUNOCHEMICALS INC.
QUIDEL CORP.
SARTORIUS
SELEXIS SA
THERMO FISHER SCIENTIFIC
WUXI APPTEC
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET OVERVIEW
Introduction
Market Potential
Regulatory Framework
United States
European Union
China
India
Japan
Brazil
Investment Analysis
Industry Growth Drivers
Advancement in Technologies Accelerating the Scale-up of Cell Lines
High Investment in Cell Culture Technology
Increasing Adoption of Cell Line Technologies in Cell-Based Assays
Surging Demand for Antibody Production
High Investments by Pharmaceutical and Biotechnology Companies in Drug Development
CHAPTER 4 MARKET BREAKDOWN BY PRODUCT
Type of Cell Line
Development of Cell Lines and Cell Culture
Immunotherapy Cell Lines
Ion Channel Cell Lines
GPCR Cell Lines
Cell Signaling Pathway Cell Lines
Gene Knockout Cell Lines
Cancer Cell Lines
Others
Type of Cell Membrane
Natural
Synthetic
CHAPTER 5 MARKET BREAKDOWN BY END USER
Biopharmaceutical Companies
Contract Research Organizations (CROs)
Academic and Research Institutes
Forensic Science Laboratories
Food and Beverage Companies
Application of Cell Lines and Cell Cultures
The Benefits of Using Plant Cell Lines:
Microbes for Food and Beverage Production
Cell Lines in Clean Meat
Diagnostic Centers
Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research in Diagnostic Centers
Cell Membrane Proteomics Can Potentially Identify Breast Cancer
Others
CHAPTER 6 MARKET BREAKDOWN BY APPLICATION
Drug Discovery and Development
Application of Cell Line and Membrane in Drug Discovery and Development Process
Surging Utilization of Cell Lines in Cancer Pharmagenomics
Clinical Trials
Basic Research
Benefits of Cell Line in Research
Toxicity Screening
Biopharmaceutical Production
The Use of Human Cell Line for Biopharmaceutical Production
The Use of CHO Cells for Biopharmaceutical Production
Driver
Drug Screening
Driver
Forensic Testing
Cell Line Authentication
Tissue Engineering
Stem Cell Applications in Tissue Engineering
Driver
CHAPTER 7 MARKET BREAKDOWN BY REGION
North America
U.S.
Canada
Europe
U.K.
Germany
France
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
Australia
ROAPAC
RoW (Rest of the World)
Latin America
Middle East and Africa
CHAPTER 8 CELL LINE AND MEMBRANE MARKET INDUSTRY STRUCTURE
Procurement of Raw Materials
Quality
Terms and Conditions
Cost Effective Components
Manufacturing/Development Process
End Users
Factors Affecting Cell Line and Membrane Market
Innovation within the Industry
Various Gene Engineering Approaches
Advancements in Cell Lines for Cancer-Based Therapies
CAR T-Cell Lines and Immune Checkpoint Inhibitors
Autologous vs. Allogenic Cells Manufacturing Process
Competitive Analysis
CHAPTER 9 COMPANY PROFILES
ABZENA
ACM BIOLABS
ATCC
BD BIOSCIENCES
BIOIVT
CATALENT INC.
CELL BIOLABS INC.
CORNING INC.
CREATIVE BIOLABS
ETUBICS CORP.
GE HEALTHCARE
IXCELLS BIOTECHNOLOGIES
LONZA GROUP LTD.
MI BIORESEARCH INC.
MERCK MILLIPORE
MILTENYI BIOTEC
NOVUS BIOLOGICALS
ROCKLAND IMMUNOCHEMICALS INC.
QUIDEL CORP.
SARTORIUS
SELEXIS SA
THERMO FISHER SCIENTIFIC
WUXI APPTEC
LIST OF TABLES
Summary Table: Global Market for Cell Line and Membrane, by Product, Through 2023
Table 1: Investment Analysis
Table 2: Investments in Cell Culture Technology
Table 3: Regional Analysis of Studies on Antibodies
Table 4: Total Global Pharmaceutical R&D Spending, 2015-2022
Table 5: Global Cell Line and Membrane Market, by Product, Through 2023
Table 6: Key Sources and Description of Biological Contamination of Cell Lines and Membranes
Table 7: Some Key Mammalian and Insect Cell Cultures
Table 8: List of Animal Cell Lines Used in Research
Table 9: Global Cell Line Market, by Type, Through 2023
Table 10: Global Cell Line Market, by Region, Through 2023
Table 11: NCI-60 Cancer Cell Lines
Table 12: Most Common Cancers, by Type, 2018
Table 13: Research Grants, by Cancer Type, August 2018
Table 14: Global Cell Membrane Market, by Type, Through 2023
Table 15: Global Pharmaceutical R&D Spending, 2015-2022
Table 16: Global Cell Membrane Market, by Region, Through 2023
Table 17: Global Cell Line and Membrane Market, by End User, Through 2023
Table 18: Global Biopharmaceutical Companies Market, by Region, Through 2023
Table 19: Cell Lines Used in the Production of Biopharmaceuticals
Table 20: Global Growth in Pharmaceutical Market, 2015 and 2020
Table 21: Global Biologics Spending, 2011 and 2016
Table 22: Global Biosimilars Spending, 2011 and 2016
Table 23: Global Contract Research Organizations (CROs) Market, by Region, Through 2023
Table 24: Drug Development, by CRO, 2017 and 2018
Table 25: Global Academic and Research Institutes Market, by Region, Through 2023
Table 26: Cell Lines Research and Development in Academic and Research Institutes, 2017 and 2018
Table 27: Global Prevalence of Dementia, 2015-2050
Table 28: Global Forensic Science Laboratories Market, by Region, Through 2023
Table 29: Global Food and Beverage Companies Market, by Region, Through 2023
Table 30: Microbial Strains Used in Food and Beverage Industries
Table 31: Global Diagnostic Centers Market, by Region, Through 2023
Table 32: Global Other End Users Market, by Region, Through 2023
Table 33: Global Cell Line and Membrane Market, by Application, Through 2023
Table 34: Global Drug Discovery and Development Market, by Region, Through 2023
Table 35: International Cancer Research Projects Share, by Region, 2017-2018
Table 36: American Chemical Society Grants, by Cancer Type, 2018
Table 37: Investment in Cancer Research in Canada, by Cancer Type, 2016
Table 38: Drugs in Development, by Disease Type, 2017
Table 39: Pharmaceutical Spending, by Country, 2016
Table 40: Global Basic Research Market, by Region, Through 2023
Table 41: U.S. R&D Funding Share, 2016
Table 42: Global Toxicity Screening Market, by Region, Through 2023
Table 43: Member Companies of the Pharmaceutical Research and Manufacturers of America R&D Investments (U.S.), 2005-2016
Table 44: Investments in Personalized Medicine, 2017 and 2018
Table 45: Global Biopharmaceutical Production Market, by Region, Through 2023
Table 46: U.S. Food and Drug Administration-Approved Protein Therapeutics, 2015-2016
Table 47: Comparison of Human Cell Lines with Other Expression Systems in the Production of Therapeutic Proteins
Table 48: Monoclonal Antibodies Approved by the European Medical Agency and Food and Drug Administration for Therapeutic Use Status, 2015-2017
Table 49: Pharmaceutical R&D Expenditure in Europe, the U.S. and Japan, 2010 and 2015
Table 50: Global Drug Screening Market, by Region, Through 2023
Table 51: Advantages and Disadvantages of the Use of Cancer Cell Lines as Models in Cancer Research
Table 52: Estimated New Cases of Leukemia, Lymphoma, and Myeloma, 2018
Table 53: Global Forensic Testing Market, by Region, Through 2023
Table 54: Current Status of SNP, STR, and DNA Barcode Technologies as Standard Methods for Assessing the Identity of Cell Lines from Different Species
Table 55: Global Tissue Engineering Market, by Region, Through 2023
Table 56: NIH Spending Trend on Stem Cell Research, 2015-2018
Table 57: Global Cell Line and Membrane Market, by Region, Through 2023
Table 58: North American Cell Line and Membrane Market, by Country, Through 2023
Table 59: NIH Spending on Stem Cell Research, 2013-2016
Table 60: North American Cell Line and Membrane Market, by Product, Through 2023
Table 61: NIH Funding for CRISPR-Related Research, 2006-2016
Table 62: North American Cell Line and Membrane Market, by End User, Through 2023
Table 63: Net Spending on Biologics in the U.S., 2013-2017
Table 64: North American Cell Line and Membrane Market, by Application, Through 2023
Table 65: Percentage Increase of Spending on Biologics in Canada, 2011-2016
Table 66: European Cell Line and Membrane Market, by Country, Through 2023
Table 67: Pharmaceutical Industry R&D Expenditures in Selected European Countries
Table 68: Cumulative Spending on Biosimilar Medicines in the EU5, 2016-2020
Table 69: European Cell Line and Membrane Market, by Product, Through 2023
Table 70: U.K. Pharmaceutical R&D Expenditures, 2014 and 2015
Table 71: European Cell Line and Membrane Market, by End User, Through 2023
Table 72: European Cell Line and Membrane Market, by Application, Through 2023
Table 73: Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2016
Table 74: Asia-Pacific Cell Line and Membrane Market, by Country, Through 2023
Table 75: Asia-Pacific Cell Line and Membrane Market, by Product, Through 2023
Table 76: Studies Recruiting Under Phase IV, Based on Cell Line
Table 77: Number of People with Cancer in China, 2010-2016
Table 78: Asia-Pacific Cell Line and Membrane Market, by Application, Through 2023
Table 79: Growth in Biotech Industry in India, 2010-2017
Table 80: Some of the Approved Biosimilar Products in India
Table 81: Growing Number of Cancer Patients in India, 2010-2016
Table 82: Asia-Pacific Cell Line and Membrane Market, by End User, Through 2023
Table 83: R&D Spending in India, by Top Pharmaceutical Companies, 2016
Table 84: List of Biotech Companies Supported by Osaka University in Cell Culture
Table 85: Estimated Most Common Cancer Diagnosed, by Type, 2018
Table 86: Commonly Diagnosed Cancers in Australia, 2017
Table 87: Rest of the World Cell Line and Membrane Market, by Country, Through 2023
Table 88: Rest of the World Cell Line and Membrane Market, by Product, Through 2023
Table 89: Rest of the World Cell Line and Membrane Market, by End User, Through 2023
Table 90: Rest of the World Cell Line and Membrane Market, by Application, Through 2023
Table 91: Global Suppliers to Cell Line and Membrane Market
Table 92: Some of the Major Cell Line and Membrane Companies
Table 93: FDA Center for Drug Evaluation and Research Approved Biologics Based on Cell Lines, 2015
Table 94: Some CRISPR-Cas-Based Gene Editing Techniques Used for Manipulation of Various Organisms
Table 95: CAR T-Cell Therapy in Immuno-Oncology Medicine Development, 2017
Table 96: Global CAR T-Cell Therapy Market, by Region, Through 2023
Table 97: Global Immune Checkpoint Inhibitor Therapy Market, by Region, Through 2023
Table 98: FDA-Approved Immune Checkpoint Inhibitors
Table 99: Global Distribution of All Studies on Immune Checkpoint Inhibitors, by Region/Country
Table 100: Autologous vs. Allogenic Cells Manufacturing Process
Table 101: Abzena: Product Portfolio
Table 102: Abzena: Recent Developments
Table 103: ACM Biolabs: Product Portfolio
Table 104: ACM Biolabs: Recent Developments, January 2018 to December 2018
Table 105: ATCC: Product Portfolio
Table 106: ATCC: Recent Developments, 2015 to September 2018
Table 107: BD Biosciences: Product Portfolio
Table 108: BioIVT: Product Portfolio
Table 109: BioIVT: Recent Developments, 2015 to September 2018
Table 110: Catalent Inc.: Product Portfolio
Table 111: Catalent Inc.: Recent Developments, 2015 to September 2018
Table 112: Cell Biolabs Inc.: Product Portfolio
Table 113: Corning Inc.: Product Portfolio
Table 114: Creative Biolabs: Product Portfolio
Table 115: Etubics Corp.: Product Portfolio
Table 116: Etubics Corp.: Recent Developments, 2015 to September 2018
Table 117: GE Healthcare: Product Portfolio
Table 118: GE Healthcare: Recent Developments, 2015 to September 2018
Table 119: iXCells Biotechnologies: Product Portfolio
Table 120: Lonza Group Ltd.: Product Portfolio
Table 121: Lonza Group Ltd.: Recent Developments, 2015 to September 2018
Table 122: MI Bioresearch Inc.: Product Portfolio
Table 123: Merck Millipore: Product Portfolio
Table 124: Merck Millipore: Recent Developments, 2015 to September 2018
Table 125: Miltenyi Biotec: Product Portfolio
Table 126: Miltenyi Biotec: Recent Developments, 2015 to September 2018
Table 127: Novus Biologicals: Product Portfolio
Table 128: Novus Biologicals: Recent Developments, 2015 to September 2018
Table 129: Rockland Immunochemicals Inc.: Product Portfolio
Table 130: Rockland Immunochemicals Inc.: Recent Developments, 2015 to September 2018
Table 131: Quidel Corp.: Product Portfolio
Table 132: Quidel Corp.: Recent Developments, 2015 to September 2018
Table 133: Sartorius: Product Portfolio
Table 134: Selexis SA: Product Portfolio
Table 135: Thermo Fisher Scientific: Product Portfolio
Table 136: Thermo Fisher Scientific: Recent Developments, 2015 to September 2018
Table 137: WuXi AppTec: Product Portfolio
Table 138: WuXi AppTec: Recent Developments, 2015 to June 2018
Summary Table: Global Market for Cell Line and Membrane, by Product, Through 2023
Table 1: Investment Analysis
Table 2: Investments in Cell Culture Technology
Table 3: Regional Analysis of Studies on Antibodies
Table 4: Total Global Pharmaceutical R&D Spending, 2015-2022
Table 5: Global Cell Line and Membrane Market, by Product, Through 2023
Table 6: Key Sources and Description of Biological Contamination of Cell Lines and Membranes
Table 7: Some Key Mammalian and Insect Cell Cultures
Table 8: List of Animal Cell Lines Used in Research
Table 9: Global Cell Line Market, by Type, Through 2023
Table 10: Global Cell Line Market, by Region, Through 2023
Table 11: NCI-60 Cancer Cell Lines
Table 12: Most Common Cancers, by Type, 2018
Table 13: Research Grants, by Cancer Type, August 2018
Table 14: Global Cell Membrane Market, by Type, Through 2023
Table 15: Global Pharmaceutical R&D Spending, 2015-2022
Table 16: Global Cell Membrane Market, by Region, Through 2023
Table 17: Global Cell Line and Membrane Market, by End User, Through 2023
Table 18: Global Biopharmaceutical Companies Market, by Region, Through 2023
Table 19: Cell Lines Used in the Production of Biopharmaceuticals
Table 20: Global Growth in Pharmaceutical Market, 2015 and 2020
Table 21: Global Biologics Spending, 2011 and 2016
Table 22: Global Biosimilars Spending, 2011 and 2016
Table 23: Global Contract Research Organizations (CROs) Market, by Region, Through 2023
Table 24: Drug Development, by CRO, 2017 and 2018
Table 25: Global Academic and Research Institutes Market, by Region, Through 2023
Table 26: Cell Lines Research and Development in Academic and Research Institutes, 2017 and 2018
Table 27: Global Prevalence of Dementia, 2015-2050
Table 28: Global Forensic Science Laboratories Market, by Region, Through 2023
Table 29: Global Food and Beverage Companies Market, by Region, Through 2023
Table 30: Microbial Strains Used in Food and Beverage Industries
Table 31: Global Diagnostic Centers Market, by Region, Through 2023
Table 32: Global Other End Users Market, by Region, Through 2023
Table 33: Global Cell Line and Membrane Market, by Application, Through 2023
Table 34: Global Drug Discovery and Development Market, by Region, Through 2023
Table 35: International Cancer Research Projects Share, by Region, 2017-2018
Table 36: American Chemical Society Grants, by Cancer Type, 2018
Table 37: Investment in Cancer Research in Canada, by Cancer Type, 2016
Table 38: Drugs in Development, by Disease Type, 2017
Table 39: Pharmaceutical Spending, by Country, 2016
Table 40: Global Basic Research Market, by Region, Through 2023
Table 41: U.S. R&D Funding Share, 2016
Table 42: Global Toxicity Screening Market, by Region, Through 2023
Table 43: Member Companies of the Pharmaceutical Research and Manufacturers of America R&D Investments (U.S.), 2005-2016
Table 44: Investments in Personalized Medicine, 2017 and 2018
Table 45: Global Biopharmaceutical Production Market, by Region, Through 2023
Table 46: U.S. Food and Drug Administration-Approved Protein Therapeutics, 2015-2016
Table 47: Comparison of Human Cell Lines with Other Expression Systems in the Production of Therapeutic Proteins
Table 48: Monoclonal Antibodies Approved by the European Medical Agency and Food and Drug Administration for Therapeutic Use Status, 2015-2017
Table 49: Pharmaceutical R&D Expenditure in Europe, the U.S. and Japan, 2010 and 2015
Table 50: Global Drug Screening Market, by Region, Through 2023
Table 51: Advantages and Disadvantages of the Use of Cancer Cell Lines as Models in Cancer Research
Table 52: Estimated New Cases of Leukemia, Lymphoma, and Myeloma, 2018
Table 53: Global Forensic Testing Market, by Region, Through 2023
Table 54: Current Status of SNP, STR, and DNA Barcode Technologies as Standard Methods for Assessing the Identity of Cell Lines from Different Species
Table 55: Global Tissue Engineering Market, by Region, Through 2023
Table 56: NIH Spending Trend on Stem Cell Research, 2015-2018
Table 57: Global Cell Line and Membrane Market, by Region, Through 2023
Table 58: North American Cell Line and Membrane Market, by Country, Through 2023
Table 59: NIH Spending on Stem Cell Research, 2013-2016
Table 60: North American Cell Line and Membrane Market, by Product, Through 2023
Table 61: NIH Funding for CRISPR-Related Research, 2006-2016
Table 62: North American Cell Line and Membrane Market, by End User, Through 2023
Table 63: Net Spending on Biologics in the U.S., 2013-2017
Table 64: North American Cell Line and Membrane Market, by Application, Through 2023
Table 65: Percentage Increase of Spending on Biologics in Canada, 2011-2016
Table 66: European Cell Line and Membrane Market, by Country, Through 2023
Table 67: Pharmaceutical Industry R&D Expenditures in Selected European Countries
Table 68: Cumulative Spending on Biosimilar Medicines in the EU5, 2016-2020
Table 69: European Cell Line and Membrane Market, by Product, Through 2023
Table 70: U.K. Pharmaceutical R&D Expenditures, 2014 and 2015
Table 71: European Cell Line and Membrane Market, by End User, Through 2023
Table 72: European Cell Line and Membrane Market, by Application, Through 2023
Table 73: Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2016
Table 74: Asia-Pacific Cell Line and Membrane Market, by Country, Through 2023
Table 75: Asia-Pacific Cell Line and Membrane Market, by Product, Through 2023
Table 76: Studies Recruiting Under Phase IV, Based on Cell Line
Table 77: Number of People with Cancer in China, 2010-2016
Table 78: Asia-Pacific Cell Line and Membrane Market, by Application, Through 2023
Table 79: Growth in Biotech Industry in India, 2010-2017
Table 80: Some of the Approved Biosimilar Products in India
Table 81: Growing Number of Cancer Patients in India, 2010-2016
Table 82: Asia-Pacific Cell Line and Membrane Market, by End User, Through 2023
Table 83: R&D Spending in India, by Top Pharmaceutical Companies, 2016
Table 84: List of Biotech Companies Supported by Osaka University in Cell Culture
Table 85: Estimated Most Common Cancer Diagnosed, by Type, 2018
Table 86: Commonly Diagnosed Cancers in Australia, 2017
Table 87: Rest of the World Cell Line and Membrane Market, by Country, Through 2023
Table 88: Rest of the World Cell Line and Membrane Market, by Product, Through 2023
Table 89: Rest of the World Cell Line and Membrane Market, by End User, Through 2023
Table 90: Rest of the World Cell Line and Membrane Market, by Application, Through 2023
Table 91: Global Suppliers to Cell Line and Membrane Market
Table 92: Some of the Major Cell Line and Membrane Companies
Table 93: FDA Center for Drug Evaluation and Research Approved Biologics Based on Cell Lines, 2015
Table 94: Some CRISPR-Cas-Based Gene Editing Techniques Used for Manipulation of Various Organisms
Table 95: CAR T-Cell Therapy in Immuno-Oncology Medicine Development, 2017
Table 96: Global CAR T-Cell Therapy Market, by Region, Through 2023
Table 97: Global Immune Checkpoint Inhibitor Therapy Market, by Region, Through 2023
Table 98: FDA-Approved Immune Checkpoint Inhibitors
Table 99: Global Distribution of All Studies on Immune Checkpoint Inhibitors, by Region/Country
Table 100: Autologous vs. Allogenic Cells Manufacturing Process
Table 101: Abzena: Product Portfolio
Table 102: Abzena: Recent Developments
Table 103: ACM Biolabs: Product Portfolio
Table 104: ACM Biolabs: Recent Developments, January 2018 to December 2018
Table 105: ATCC: Product Portfolio
Table 106: ATCC: Recent Developments, 2015 to September 2018
Table 107: BD Biosciences: Product Portfolio
Table 108: BioIVT: Product Portfolio
Table 109: BioIVT: Recent Developments, 2015 to September 2018
Table 110: Catalent Inc.: Product Portfolio
Table 111: Catalent Inc.: Recent Developments, 2015 to September 2018
Table 112: Cell Biolabs Inc.: Product Portfolio
Table 113: Corning Inc.: Product Portfolio
Table 114: Creative Biolabs: Product Portfolio
Table 115: Etubics Corp.: Product Portfolio
Table 116: Etubics Corp.: Recent Developments, 2015 to September 2018
Table 117: GE Healthcare: Product Portfolio
Table 118: GE Healthcare: Recent Developments, 2015 to September 2018
Table 119: iXCells Biotechnologies: Product Portfolio
Table 120: Lonza Group Ltd.: Product Portfolio
Table 121: Lonza Group Ltd.: Recent Developments, 2015 to September 2018
Table 122: MI Bioresearch Inc.: Product Portfolio
Table 123: Merck Millipore: Product Portfolio
Table 124: Merck Millipore: Recent Developments, 2015 to September 2018
Table 125: Miltenyi Biotec: Product Portfolio
Table 126: Miltenyi Biotec: Recent Developments, 2015 to September 2018
Table 127: Novus Biologicals: Product Portfolio
Table 128: Novus Biologicals: Recent Developments, 2015 to September 2018
Table 129: Rockland Immunochemicals Inc.: Product Portfolio
Table 130: Rockland Immunochemicals Inc.: Recent Developments, 2015 to September 2018
Table 131: Quidel Corp.: Product Portfolio
Table 132: Quidel Corp.: Recent Developments, 2015 to September 2018
Table 133: Sartorius: Product Portfolio
Table 134: Selexis SA: Product Portfolio
Table 135: Thermo Fisher Scientific: Product Portfolio
Table 136: Thermo Fisher Scientific: Recent Developments, 2015 to September 2018
Table 137: WuXi AppTec: Product Portfolio
Table 138: WuXi AppTec: Recent Developments, 2015 to June 2018
LIST OF FIGURES
Summary Figure: Global Market for Cell Line and Membrane, by Product, 2017-2023
Figure 1: Types of Cell Line Technologies
Figure 2: Total Global Pharmaceutical R&D Spending, 2015-2022
Figure 3: PhRMA Member Company R&D Expenditures, 2010 and 2016
Figure 4: Process of Deriving a Cell Line
Figure 5: Type of Cell Lines
Figure 6: Process of Growing Cell Lines and Delivering to Patients
Figure 7: Production Process of Ion Channel Cell Line
Figure 8: GPCR Cell Line Development Process
Figure 9: Applications of Cell Signaling Pathway Cell Lines
Figure 10: Generation of Knockout Cell Lines
Figure 11: Most Common Cancers, by Type, 2018
Figure 12: Production Process of Monoclonal Antibodies from Hybridoma Cell Lines
Figure 13: Global Pharmaceutical R&D Spending, 2015-2022
Figure 14: Common Benefits of Human Cell Lines in the Production of Therapeutic Proteins
Figure 15: Biopharmaceutical Production Using Mammalian Cells
Figure 16: Global Growth in Pharmaceutical Market, 2015 and 2020
Figure 17: Global Biologics Spending, 2011 and 2016
Figure 18: Global Biosimilars Spending, 2011 and 2016
Figure 19: Cell Lines and Membranes Application in Academic and Research Institutes
Figure 20: Global Prevalence of Dementia, 2015-2050
Figure 21: Advantages of Short Tandem Repeat Profiling in Cell Line Authentication
Figure 22: Workflow for Authentication of Cell Lines
Figure 23: Clean Meat Development Process Through Cell Lines
Figure 24: Meat Consumption, 2015-2027
Figure 25: Workflow Outlines Process of Obtaining Plasma Membrane Proteome of Multiple BC Cell Lines
Figure 26: Storage of Cell Lines in Cell Bank
Figure 27: Major Factors Driving the Growth of the Cell Line and Membrane Market, by Application
Figure 28: International Cancer Research Projects Share, by Region, 2017-2018
Figure 29: Drugs Share in Development, by Disease Type, 2017
Figure 30: Pharmaceutical Spending, by Country, 2016
Figure 31: U.S. R&D Funding Share, 2016
Figure 32: Member Company of Pharmaceutical Research and Manufacturers of America R&D Investment (U.S.), 2005-2016
Figure 33: Pharmaceutical R&D Expenditure in Europe, U.S. and Japan, 2010 and 2015
Figure 34: STR Analysis of Cell Lines
Figure 35: The Basic Materials and Processes Needed for Tissue Engineering Technologies
Figure 36: NIH Spending Trend on Stem Cell Research, 2015-2018
Figure 37: NIH Spending on Stem Cell Research, 2013-2016
Figure 38: Net Spending on Biologics in the U.S., 2013-2017
Figure 39: Pharmaceutical Industry R&D Expenditure in Selected European Countries
Figure 40: U.K. Pharmaceutical R&D Expenditures, 2014 and 2015
Figure 41: Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2016
Figure 42: Number of People with Cancer in China, 2010-2016
Figure 43: Growth in Biotech Industry in India, 2010-2017
Figure 44: Growing Number of Cancer Patients in India, 2010-2016
Figure 45: R&D Spending in India, by Top Pharmaceutical Companies, 2016
Figure 46: Japan Pharmaceuticals Industry, 2010-2015
Figure 47: Estimated Most Common Cancer Diagnosed, by Type, 2018
Figure 48: Industry Structure of the Cell Line and Membrane Market
Figure 49: Cell Line Development Flow chart
Figure 50: CAR T-Cell Therapy Mechanism
Figure 51: Global CAR T-Cell Therapy Market, by Region, 2017-2023
Figure 52: Global Immune Checkpoint Inhibitor Therapy Market, by Region, 2017-2023
Figure 53: Global Distribution of All Studies on Immune Checkpoint Inhibitors, by Region/Country
Figure 54: Competitive Analysis Share for Cell Line and Membrane Market, by Strategies
Summary Figure: Global Market for Cell Line and Membrane, by Product, 2017-2023
Figure 1: Types of Cell Line Technologies
Figure 2: Total Global Pharmaceutical R&D Spending, 2015-2022
Figure 3: PhRMA Member Company R&D Expenditures, 2010 and 2016
Figure 4: Process of Deriving a Cell Line
Figure 5: Type of Cell Lines
Figure 6: Process of Growing Cell Lines and Delivering to Patients
Figure 7: Production Process of Ion Channel Cell Line
Figure 8: GPCR Cell Line Development Process
Figure 9: Applications of Cell Signaling Pathway Cell Lines
Figure 10: Generation of Knockout Cell Lines
Figure 11: Most Common Cancers, by Type, 2018
Figure 12: Production Process of Monoclonal Antibodies from Hybridoma Cell Lines
Figure 13: Global Pharmaceutical R&D Spending, 2015-2022
Figure 14: Common Benefits of Human Cell Lines in the Production of Therapeutic Proteins
Figure 15: Biopharmaceutical Production Using Mammalian Cells
Figure 16: Global Growth in Pharmaceutical Market, 2015 and 2020
Figure 17: Global Biologics Spending, 2011 and 2016
Figure 18: Global Biosimilars Spending, 2011 and 2016
Figure 19: Cell Lines and Membranes Application in Academic and Research Institutes
Figure 20: Global Prevalence of Dementia, 2015-2050
Figure 21: Advantages of Short Tandem Repeat Profiling in Cell Line Authentication
Figure 22: Workflow for Authentication of Cell Lines
Figure 23: Clean Meat Development Process Through Cell Lines
Figure 24: Meat Consumption, 2015-2027
Figure 25: Workflow Outlines Process of Obtaining Plasma Membrane Proteome of Multiple BC Cell Lines
Figure 26: Storage of Cell Lines in Cell Bank
Figure 27: Major Factors Driving the Growth of the Cell Line and Membrane Market, by Application
Figure 28: International Cancer Research Projects Share, by Region, 2017-2018
Figure 29: Drugs Share in Development, by Disease Type, 2017
Figure 30: Pharmaceutical Spending, by Country, 2016
Figure 31: U.S. R&D Funding Share, 2016
Figure 32: Member Company of Pharmaceutical Research and Manufacturers of America R&D Investment (U.S.), 2005-2016
Figure 33: Pharmaceutical R&D Expenditure in Europe, U.S. and Japan, 2010 and 2015
Figure 34: STR Analysis of Cell Lines
Figure 35: The Basic Materials and Processes Needed for Tissue Engineering Technologies
Figure 36: NIH Spending Trend on Stem Cell Research, 2015-2018
Figure 37: NIH Spending on Stem Cell Research, 2013-2016
Figure 38: Net Spending on Biologics in the U.S., 2013-2017
Figure 39: Pharmaceutical Industry R&D Expenditure in Selected European Countries
Figure 40: U.K. Pharmaceutical R&D Expenditures, 2014 and 2015
Figure 41: Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2016
Figure 42: Number of People with Cancer in China, 2010-2016
Figure 43: Growth in Biotech Industry in India, 2010-2017
Figure 44: Growing Number of Cancer Patients in India, 2010-2016
Figure 45: R&D Spending in India, by Top Pharmaceutical Companies, 2016
Figure 46: Japan Pharmaceuticals Industry, 2010-2015
Figure 47: Estimated Most Common Cancer Diagnosed, by Type, 2018
Figure 48: Industry Structure of the Cell Line and Membrane Market
Figure 49: Cell Line Development Flow chart
Figure 50: CAR T-Cell Therapy Mechanism
Figure 51: Global CAR T-Cell Therapy Market, by Region, 2017-2023
Figure 52: Global Immune Checkpoint Inhibitor Therapy Market, by Region, 2017-2023
Figure 53: Global Distribution of All Studies on Immune Checkpoint Inhibitors, by Region/Country
Figure 54: Competitive Analysis Share for Cell Line and Membrane Market, by Strategies
